Hormonally regulated survival factors can have an important role in breast cancer. Here we elucidate G1P3, a survival protein induced by interferons (IFNs), as a target of estrogen signaling and a contributor to poor outcomes in estrogen receptor-positive (ER þ ) breast cancer. Compared with normal breast tissue, G1P3 was upregulated in the malignant epithelium (50 Â higher) and was induced by estrogen ex vivo. In accord with its overexpression in early stages of breast cancer (hyperplasia and ductal carcinoma in situ), in morphogenesis assays G1P3 enhanced the survival of MCF10A acinar luminal cells causing hyperplasia by suppressing detachmentinduced loss of mitochondrial potential and apoptosis (anoikis). In cells undergoing anoikis, G1P3 attenuated the induction of Bim protein, a proapoptotic member of the Bcl-2 family and reversed the downmodulation of Bcl-2 protein. Downregulation of G1P3 induced spontaneous apoptosis in BT-549 breast cancer cells and significantly reduced the growth of ER þ breast cancer cell MCF7 (Pp0.01), further suggesting its prosurvival activity. In agreement with its induction by estrogen, G1P3 antagonized tamoxifen, an inhibitor of ER in MCF7 cells. More importantly, elevated expression of G1P3 was significantly associated with decreased relapsefree and overall survival in ER þ breast cancer patients (Pp0.01). Our studies suggest that elevated expression of G1P3 may perturb canonical tumor-suppressing activity of IFNs partly by affecting the balance of pro-and antiapoptotic members of Bcl-2 family proteins, leading to breast cancer development and resistance to therapies.
Introduction
The immune system, a critical component of tumor surveillance, may drive cancer cell outgrowth upon chronic activation (de Visser et al., 2006; DeNardo et al., 2008) . However, molecular factors that mediate tumorpromoting effects of immune signaling remain undefined. Interferons (IFNs) are a group of cytokines that are an integral part of immune surveillance and can eradicate malignant cells as they emerge (Dunn et al., 2006; Borden et al., 2007) . Accordingly, upregulated IFN-stimulated genes (ISGs) in cancers, including breast, have been suggested to reflect activation of the innate immune system and thus be beneficial (Einav et al., 2005; Bektas et al., 2008) . In contrast, recent studies suggest that IFNs and other inflammatory cytokines may augment tumor progression (de Visser et al., 2006; Calogero et al., 2007; DeNardo and Coussens, 2007; Bektas et al., 2008; DeNardo et al., 2008) . ISG signatures that may be predictive of DNA damage resistance in bronchial and breast carcinomas have been described (Einav et al., 2005; Weichselbaum et al., 2008; Luszcek et al., 2010) . Supporting the potential pro-tumor activity of some ISGs, we and others identified G1P3 (ISG 6-16, IFI6), a gene robustly stimulated by IFNs, as an antiapoptotic protein (Tahara et al., 2005; Cheriyath et al., 2007) .
G1P3 was first identified as an ISG more than two decades ago and encodes three splice variants of 130-138 amino acids (B13 kDa) (Friedman et al., 1984; Parker and Porter, 2004; Cheriyath et al., 2010) . G1P3 antagonized intrinsic apoptosis by IFNs and tumor necrosis factor-related apoptosis-inducing ligand in myeloma cells and by 5-fluorouracil in gastric cancer cells (Tahara et al., 2005; Cheriyath et al., 2007) . These were the first functional insights into the cellular effects of G1P3. Consistent with its inhibitory effects on intrinsic apoptosis, G1P3 localized into the mitochondria of both myeloma and gastric cancer cells (Tahara et al., 2005; Cheriyath et al., 2007) .
Based on its prosurvival activity, we postulated that constitutively expressed G1P3 may confer survival advantages to epithelial cells to augment cancer development and progression. As expression array studies suggested upregulation of ISGs including G1P3 in breast cancers (Sorbello et al., 2003; Bani et al., 2004; Tsai et al., 2007) , we tested the functional consequence of G1P3 upregulation in breast cancer development and progression. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and in situ hybridization identified marked upregulation of G1P3 in early and advanced breast carcinomas compared with nonmalignant breast epithelium. Further investigation identified G1P3 as a target of estrogen signaling, with a role in the formation of hyperplasia and tamoxifen resistance. Consistent with its prosurvival effects, elevated expression of G1P3 significantly correlated with worse prognosis in breast cancer patients.
Results

G1P3 is overexpressed in breast carcinomas and is induced by estrogen signaling
To validate and quantify G1P3 overexpression in breast cancers, G1P3 mRNA levels were compared in 11 breast carcinomas, normal breast (NB) tissue and human mammary epithelial cells (HMECs) by qRT-PCR. Relative to NB and HMECs, the expression of G1P3 was significantly higher in invasive ductal carcinomas (IDCs) and in ductal carcinomas in situ (DCIS) (Figure 1a) .
The increased expression of G1P3 in tumor stromal cells could lead to the observed overall increased expression of G1P3 in biopsies. To rule out this possibility, qRT-PCR was undertaken on RNA isolated from laser-dissected malignant cells. As in whole biopsies, relative to NB cells, G1P3 mRNA levels were up to 50-fold higher in laser-dissected malignant cells (Figure 1b) . Similar G1P3 expression in whole biopsies and microdissected malignant cells suggested a minimal contribution of stromal cells to overall G1P3 expression in biopsies.
As currently available antibodies to G1P3, including the one that we developed (pAB609), are incompatible for immunohistochemistry, in situ hybridization with a G1P3-specific locked nucleic acid (G1P3-LNA) was performed to confirm the malignant epithelial cellspecific expression of G1P3 mRNA. The specificity of G1P3-LNA probe and hybridization methods were optimized using MDA-MB-231 cells (a breast cancer cell line with very low levels of basal G1P3 mRNA) transduced with vector or G1P3 cDNA (Supplementary Figure 1) . Compared with normal and benign fibroadenoma, G1P3 mRNA expression was higher and more frequent in hyperplasia, DCIS, IDC and lobular carcinomas ( Figure 1c and Supplementary Table 1 ). In agreement with qRT-PCR results, the expression of G1P3 was confined to epithelial cells with minimal expression in stromal cells (Figures 1b and c) .
To complement mRNA studies, G1P3 protein expression was compared in non-malignant and in a panel of breast cancer cell lines representing intrinsic subtypes of breast cancer. Immunoblot analyses with affinitypurified rabbit polyclonal antibody for G1P3 identified elevated expression of G1P3 protein in 1/2 basal A (HCC 1569 and HCC1937), 3/4 basal B (BT549, HCC38, HCC1500 and MDA-MB-436) and 1/2 luminal (MDA-MB-453 and MCF7) breast cancer cell lines relative to MCF10A, an immortalized mammary epithelial cell line with normal karyotype (Figure 1d ).
The overexpression of G1P3 in breast cancer was further confirmed by in silico analysis of a publicly available gene expression data set (Cheng et al., 2008; Chen et al., 2010) . Compared with NB tissues (n ¼ 10), G1P3 expression was markedly higher (B4.0 Â ) in IDC (n ¼ 22), but not in adjacent non-malignant tissues with fibrocystic abnormalities (n ¼ 7) (Supplementary Figure  2 and Supplementary Table 2 ). Compared with normal tissues, the median expression of G1P3 mRNA was also upregulated in luminal A, luminal B and basal subtypes of IDCs by 1.2 Â , 1.3 Â and 1.4 Â , respectively . In addition, G1P3 mRNA was overexpressed in several other cancer histologies, including head and neck cancer (GSE9844), hepatocellular carcinoma (GSE6764) and pancreatic cancer (Haqq et al., 2005; Segara et al., 2005; Wurmbach et al., 2007; Ye et al., 2008; Supplementary Table 3 and www. oncomine.org).
As G1P3 was constitutively expressed in an estrogen receptor-positive (ER þ ) and estrogen-dependent breast cancer cell line, MCF7 (Figure 1d ), the role of estrogen in the induction of G1P3 was investigated. Both tamoxifen (an ER inhibitor) and estrogen starvation markedly reduced the expression of G1P3 (Figure 1e , lanes 2 and 3). However, treatment of estrogen-starved cells with IFN-a2b, IFNg or 17b-estradiol induced G1P3 protein (Figure 1e , lanes 4-6). These agents also induced G1P3 mRNA expression in HMECs (Figure 1f ). These results suggested that G1P3 is a target of both IFN and estrogen signaling in breast cells.
G1P3 inhibits luminal cell death of MCF10A acini
It was unclear as to whether elevated G1P3 had an active role in breast cancer pathobiology or was an epiphenomenon. As G1P3 was overexpressed in the epithelia of early stages of breast cancer (DCIS and hyperplasia), its role in ductal carcinoma development was investigated in morphogenesis assays with MCF10A cells expressing either vector (MCF10A Vector ) or G1P3 (MCF10A G1P3 ) ( Figure 2a) . In morphogenesis assays, MCF10A form structures resembling normal acini with hollow lumens. Overexpression of oncogenes and antiapoptotic genes disrupts luminal cell clearance causing hyperplastic or neoplastic acini with filled lumen Mailleux et al., 2008a; Weigelt and Bissell, 2008) .
On day 11, MCF10A Vector formed hollow glandular acini, whereas MCF10A G1P3 formed hyperplastic acini with filled lumens (Figure 2b 
MCF10A
Vector acini were cleared forming a hollow lumen, whereas the MCF10A G1P3 acinar luminal cell numbers remained similar (Figures 2c and d (Idziorek et al., 1995) . In MCF10A
Vector acini, a rapid increase in cell death was observed between day 8 (17%) and day 12 (55%), followed by a decrease suggesting near-complete luminal cell death (Figure 2e ). In MCF10A G1P3 acini, B10% of acini were positive for apoptosis on day 12 and 23% on day 26, indicating the onset of luminal cell death at a later stage (Figure 2e ).
To confirm antiapoptotic effect of G1P3 on luminal cells, caspase 3 activation in MCF10A Vector and MCF10A
G1P3 acini was tested on days 5, 8 and 10 by indirect immunofluorescence microscopy with an antibody specific to cleaved caspase 3. In MCF10A Vector acini, the caspase 3 activation was initiated on day 5 with a marked increase in activity on day 10. Compared with MCF10A
Vector acini, a marked reduction in the activation of caspase 3 was observed in MCF10A G1P3 acini ( Figure 2f ). In addition, MCF10A Vector and MCF10A G1P3 acini were harvested on days 5 and 10 and caspase 3 cleavage was confirmed by immunoblot analysis and apoptosis was quantified as described (Reginato et al., 2003; Anderson et al., 2010) . In immunoblots, caspase 3 cleavage was absent on day 5; however, caspase 3 was cleaved in MCF10A Vector acini lysates on day 10, but not in MCF10A G1P3 acini, which is in agreement with the results of immunofluorescence studies (Figure 2g ). Further, there was a fourfold reduction (Po0.0001) in apoptosis in MCF10A G1P3 acini (as measured by mono-and oligonucleosomes in the cytoplasmic fraction of acinar lysates; Figure 2h ).
G1P3 inhibits detachment-induced cell death (anoikis) of mammary epithelial cells and inhibits apoptosis of breast cancer cells Detachment-induced cell death (anoikis) has a major role in clearing luminal cells during acini formation. Thus, effects of G1P3 on anoikis were evaluated using passage-matched, stable pools of MCF10A transductants. Only 3.7% of adherent MCF10A
Vector cells were positive for cell death that increased to 43.2% after 24 h of detachment from matrix ( Figure 3a) . Although cell death of MCF10A Vector and MCF10A G1P3 was similar in cells attached to matrix, anoikis was significantly reduced to 19.5% and 27.5% at 24 and 36 h, respectively, in G1P3-overexpressing cells (Po0.01; Figure 3a ). Assessing anoikis with viability stain propidium iodide also resulted in similar results (Supplementary Figure 3) .
Antagonistic effect of G1P3 on anoikis was further confirmed by assessing detachment-induced apoptosis and poly-(ADP-ribose) polymerase cleavage. In cells attached to the matrix, there was no significant difference in apoptosis either at 24 or 36 h ( Figure 3b ). Upon detachment from the matrix, apoptosis markedly increased in MCF10A
Vector cells (5-fold increase at 24 h and B6-fold increase at 36 h). Compared with Figure 1 G1P3 is upregulated in malignant breast epithelium and induced by estrogen. (a) G1P3 mRNA overexpression in breast carcinomas. In all, 11 IDCs, and 2 DCIS and HMECs were analyzed by qRT-PCR and fold change of G1P3 mRNA over NB was calculated. Each box-plot signifies three independent experiments. (b) Malignant mammary epithelial cell-specific expression of G1P3 mRNA. Regions with X95% malignant epithelial cells were laser dissected from IDC-2, -3, -6, -9 and -11 biopsies. G1P3 mRNA expression in tumor cells relative to NB was assessed by qRT-PCR. Each bar represents mean ± s.e.m. of three independent assays. (c) G1P3 mRNA expression in malignant and non-malignant breast epithelium by in situ hybridization. Breast tissue array BRC961 (Biomax.us) containing 48 breast tissue cores in duplicate was subjected to in situ hybridization with either G1P3-or b-actin-LNA probes. Images at Â 20 and Â 40 Â were acquired using Leica DMR microscope with Q-imaging Retiga Exi camera and the ImagePro software (Mediacybernetics, Bethesda, MD, USA). Role of the antiapoptotic factor G1P3 in breast cancer V Cheriyath et al
Vector , there was a 2.6-fold reduction in anoikis in G1P3-expressing cells at 24 h and 2.2-fold at 36 h (Po0.001; Figure 3b ). In agreement with these results, relative to MCF10A Vector , PARP cleavage was reduced in MCF10A G1P3 cells at 24 and 36 h after detachment from matrix ( Figure 3c ).
G1P3 antagonizes anoikis-induced loss of mitochondrial potential and affects the expression of Bcl-2 and Bim proteins As in myeloma and in gastric cancer cells G1P3 inhibited apoptosis by antagonizing loss of mitochondrial potential (Dc) (Tahara et al., 2005; Vector or MCF10A G1P3 were fixed and nuclei were stained with 4 0 ,6-diamidino-2-phenylindole. Acini on days 8 and 11 were imaged by confocal microscopy at Â 20 magnification at zoom 2; day 26 acini were imaged at Â 10 magnification. (c) Ectopic G1P3 markedly reduced clearance of inner luminal cells of MCF10A acini. The number of luminal cells in the midsections of 20 acini on indicated days was counted. Each graph point is mean ± s.e.m. of two independent experiments. (d) Ectopic G1P3 markedly increased the percentage of hyperplastic acini. Acini from 10 confocal fields at Â 10 magnification were counted to determine percentage of acini with filled lumens. Each point in graph is mean ± s.e.m. of two independent experiments. (e) G1P3's effect on inner luminal cell survival. Live acini were stained with Hoechst 33342 (blue), Yo-Pro (green) and PI (red) on indicated days (day 11 in left panel). In all, 100 acini were imaged per time point with a Leica DMI4000B inverted microscope and percentage of acini stained with Yo-Pro was determined (right panel). Each data point is mean ± s.e.m. of three independent experiments. (f) Caspase 3 activation was suppressed in G1P3-expressing acini. Immunostaining with anti-caspase 3 antibody was performed on MCF10A
Vector and MCF10A
G1P3
acini using an Alexa Fluor 488 (green)-conjugated secondary antibody. The nuclei were visualized by 4 0 ,6-diamidino-2-phenylindole and confocal images were overlapped to obtain merged images. Images are a representative of two independent experiments. (g) Ectopically expressed G1P3 inhibits caspase 3 cleavage in MCF10A acini. Acini on days 5 and 10 were harvested and caspase 3 cleavage was determined by subjecting 30 mg of lysates for immunoblot analysis and b-actin was used as a loading control. (h) G1P3 inhibits cell death in MCF10A acini. Lysates from day 10 MCF10A
Vector and MCF10A G1P3 acini were assessed for apoptosis. Cells harvested from two-dimensional (2D) culture conditions were used as a negative control. Values represent the mean ± s.e.m. of A 405 -A 490 from three independent experiments.
Role of the antiapoptotic factor G1P3 in breast cancer V Cheriyath et al et al., 2007) , therefore, its effect on anoikis-induced mitochondrial permeability transition of MCF10A cells was investigated. Both endogenous and ectopically expressed G1P3 localized primarily into mitochondrial fractions (Figure 4a ). In kinetic studies under anoikisinducing conditions, 24.7% of MCF10A Vector cells lost their Dc at 8 h, which increased to 28.5% and 46.4% at 24 and 36 h, respectively (Figure 4b ). In contrast, significantly (P ¼ 0.001) fewer MCF10A G1P3 cells lost Dc under detachment conditions (9.8% at 8 h, 9.2% at 24 h and 14.2% at 36 h; Figure 4b ).
To gain an understanding of whether G1P3 itself or in cooperation with other factors mediates the stabilization of mitochondria, the expression of pro-(Bim and Bid) and antiapoptotic (Bcl-2) members of the Bcl-2 family suggested to be involved in anoikis was investigated. Compared to cells attached to the matrix, there was a marked reduction in the expression of Bcl-2 protein, but Bim and Bid proteins were induced in MCF10A Vector cells undergoing anoikis (Figure 4c ). However, in MCF10A G1P3 cells undergoing anoikis, a similar level of Bcl-2 protein was observed with a marked reduction in Bim protein level and no change in Bid protein level compared with cells attached to the matrix ( Figure 4c ). Next, we tested whether the increased Bcl-2 protein in MCF10A G1P3 cells undergoing anoikis was due to increased Bcl-2 mRNA by qRT-PCR. Although there was a slight reduction in the expression of Bcl-2 mRNA upon anoikis, this was not significant (PX0.05), and the expression of Bcl-2 mRNA was similar in MCF10A Vector and MCF10A G1P3 cells (Figure 4d ). G1P3 may thus in part confer resistance to anoikis by modulating the balance between the expression of Bcl-2 and Bim proteins at the post-transcriptional level.
Constitutively expressed G1P3 augments survival and tamoxifen resistance in breast cancer cells Epithelial cells can acquire resistance to detachmentinduced cell death early on during neoplastic transformation and become resistant to apoptosis (Debnath et al., 2002; Swan et al., 2003; Bharadwaj et al., 2005) . Therefore, the contribution of constitutively expressed G1P3 to spontaneous apoptosis and cell survival was assessed by downregulating its expression with small interfering RNA (siRNA) in BT-549 and MCF7 cells (Figures 5a and b) . Control siRNA had no apparent Role of the antiapoptotic factor G1P3 in breast cancer V Cheriyath et al effect on G1P3 expression or apoptosis when assessed by immunoblot and TdT-mediated dUTP nick-end labeling assays, respectively. However, transient downregulation of G1P3 with siRNA significantly increased apoptosis of BT-549 cells from 1.9 to 14.7% at 48 h post-transfection, supporting the antiapoptotic role of G1P3 in breast cancer cells (Po0.001; Figure 5a ). Similarly, downregulation of constitutively expressed G1P3 significantly reduced the growth of MCF7-and G1P3-overexpressing MCF7 G1P3 cells 450% (Po0.01; Figure 5b ).
As G1P3 was a target of estrogen signaling and supported the survival of ER þ breast cancer cell MCF7, its role in antagonizing tamoxifen-mediated growth suppression was tested. As tamoxifen inhibited the expression of G1P3 (Figure 1e ), constitutive expression of G1P3 in MCF7 cells was achieved by expressing it heterologously under a cytomegalovirus promoter (Figure 5c ). Compared with vector-transduced MCF7 (MCF7 Vector ), MCF7 G1P3 cells were resistant to tamoxifen in clonogenic assays with an median inhibitory IC 50 concentration of 2.2 and 5.6 mM, respectively (Figure 5c ). In agreement with these results, knockdown of G1P3 either in MCF7
Vector or MCF7 G1P3 cells sensitized them to tamoxifen, further demonstrating the role of G1P3 in conferring survival advantages and tamoxifen resistance in ER þ breast cancer cells (Figure 5d ).
Elevated expression of G1P3 associated with reduced relapse-free and overall survival in ER þ breast cancer patients To test the postulate that elevated expression of G1P3 might correlate with poor prognosis in breast cancer patients, four publicly available gene expression data sets were analyzed to determine the impact of G1P3 on relapse-free survival (RFS) and overall survival (OS) Vector and MCF10A G1P3 cells attached to matrix and undergoing anoikis were determined by relative RT-PCR using GAPDH as internal control. Each bar on the graph is mean±s.e.m. of two independent experiments carried out in duplicates.
Role of the antiapoptotic factor G1P3 in breast cancer V Cheriyath et al et al., 2007) (Supplementary Table 4) . RFS data were available for all four studies, whereas OS data were available only for three (Supplementary Table 5 ).
G1P3 expression was classified as high or low using two approaches: median approach and scaled recursive partitioning (scaled RP) approach as described in Materials and methods. In univariate analysis, elevated Vector and MCF7 G1P3 cells were subjected clonogenic assays in the presence of increasing concentrations of tamoxifen (middle panel). Each point on the nonlinear regression analysis curve is mean ± s.e.m. of two independent experiments (right panel). (d) Effects of G1P3 knockdown on tamoxifen sensitivity in MCF7 cells. Growth of MCF7 and MCF7 G1P3 cells transfected with Control or G1P3 siRNAs was determined by sulforhodamine B growth assay (right and left panels). Each point on the graph is a representative of three independent experiments carried out in duplicate.
Role of the antiapoptotic factor G1P3 in breast cancer V Cheriyath et al G1P3 expression, increased grade, ER status and lymph node positivity were significantly associated with decreased RFS and OS (all Po0.04; Table 1a ). By scaled RP approach, elevated G1P3 expression had a hazard ratio (HR) of 1.46 for RFS (P ¼ 0.003; Table 1a ). Consistent with increased risk of relapse, elevated G1P3 had an HR of 1.40 for OS. These results are consistent with RFS and OS results based on the median approach (data not shown). In multivariate analysis, G1P3 expression, ER status and lymph node positivity were identified as independent predictors of RFS (P ¼ 0.03; Table 1b.1). Elevated G1P3 expression increased the risk of relapse by 45% by scaled RP approach (HR ¼ 1.45, P ¼ 0.005; Table 1b.1). In spite of its strong association with RFS, elevated G1P3 expression had only a marginal impact on OS (HR ¼ 1.36, P ¼ 0.07; Table 1b.1). Further stratification of patients based on their ER positivity identified confinement of the adverse effect of G1P3 into the ER þ cohorts (Tables 1b.2 and 1b. 3). In ER þ cohorts, elevated expression of G1P3 increased the 5-year disease relapse by 9% (83% in G1P3 low vs 74% in G1P3 high) and reduced the 5-year OS by 6% (92% in G1P3 low vs 86% in G1P3 high) with an HR of 1.51 (P ¼ 0.01) and 1.81 (P ¼ 0.01), respectively, for RFS and OS (Table 1b. 3). Although G1P3 also had a negative impact in the ER À cohort, it did not reach statistical significance (P40.05 for RFS and OS; Table 1b .2).
Kaplan-Meier graphs summarize the impact of G1P3 expression on RFS and OS in all breast cancer patients and in ER þ cohorts (Figures 6a and b) . In both scaled RP (Figures 6a and b) and study-specific median approach (Supplementary Figure 5) , elevated expression of G1P3 significantly associated with poor reduced OS and RFS in ER þ breast cancer patients. These results demonstrate that elevated G1P3 expression is associated with adverse outcome in human breast cancer independent of commonly used prognostic and predictive factors, which highlights the significance of the survival functions of G1P3 in breast cancer.
Discussion
An association between chronically activated cytokines and cancer development and progression has long been proposed (de Visser et al., 2006; DeNardo and Coussens, 2007; Radisky and Radisky, 2007; Mantovani et al., 2008; Weigelt and Bissell, 2008) . Contrary to evidence for IFNs as suppressive factors in cancer evolution, recent studies suggested that some of its target genes (ISGs) may contribute to the progression of malignancies (Tahara et al., 2005; Cheriyath et al., 2007; Bektas et al., 2008; Weichselbaum et al., 2008; Luszcek et al., 2010) . However, the functional consequence of upregulated ISGs in cancer development and progression has not been well delineated (Sorbello et al., 2003; Bektas et al., 2008; Weichselbaum et al., 2008) .
Although IFNs can manifest antitumor effects through proapoptotic ISGs like tumor necrosis factorrelated apoptosis-inducing ligand, we identified G1P3, a highly induced ISG, as antagonistic to tumor necrosis factor-related apoptosis-inducing ligand and IFN-a2b in myeloma cells (Cheriyath et al., 2007) . As G1P3 was antiapoptotic, we postulated that overexpressed G1P3 might confer survival advantages to epithelial cells, promoting cancer development and progression. Table 1  and Supplementary Table 1 ). Both in situ hybridization and qRT-PCR of laser-dissected malignant breast carcinomas suggested confinement of G1P3 expression to premalignant or malignant breast epithelium (Figure 1) .
Although G1P3 is a confirmed ISG, in breast cells it was also a target of estrogen signaling (Figure 1 ). The presence of seven consensus estrogen regulatory elements on the G1P3 promoter also supports this finding (data not shown). ISG12a, another member of G1P3 superfamily, was first identified through differential screening of genes under estrogen control (Rasmussen et al., 1993; Cheriyath et al., 2010 Cheriyath et al., , 2011 . Taken together, these results suggest potential crosstalk between IFNs and estrogen networks in ISG regulation. The presence of G1P3 in ER-negative cell lines (Figure 1d ) and lack of correlation between G1P3 expression and mediators of IFNs signaling (JAK-STAT pathway) suggests involvement of signaling pathways other than IFNs and estrogen in its regulation (data not shown).
Consistent with the central role of mitochondria in energy production and apoptosis, its membrane potential is tightly regulated by several proteins, including opposing activities of pro-and antiapoptotic members of the Bcl-2 protein family. When epithelial cells lose their contact with extracellular matrix, proapoptotic factors like Bim are induced and elicit cell death (Figure 4c ; Reginato et al., 2003; Mailleux et al., 2007b) . On the other hand, overexpression of the antiapoptotic Bcl-2 protein inhibits luminal cell apoptosis to cause hyperplasia until day 22 (Mailleux et al., 2007a; Hebner et al., 2008) . Our results suggest that in mammary epithelial cells, G1P3 may affect the balance between Bcl-2 and Bim expression to stabilize mitochondria, leading to an augmented survival of luminal cells to cause hyperplasia (Figure 4 ). Similar levels of Bcl-2 mRNA in MCF10A
Vector and MCF10A G1P3 cells undergoing anoikis suggest that G1P3 is modulating the expression of Bcl-2 post-transcriptionally, but the mechanisms responsible are unclear. Contrary to Bcl-2, which suppressed luminal cell death until day 22, G1P3 maintained a similar number of cells on day 26 as that of day 11 (Figure 2e ; (Mailleux et al., 2007a; Hebner et al., 2008) , suggesting the involvement of other mechanisms independent of Bcl-2 in mediating the prolonged antiapoptotic action of G1P3.
Based on increased G1P3 expression in hyperplastic epithelia and DCIS, we postulated that the antiapoptotic activity of G1P3 might play a role in breast oncogenesis by affecting formation of normal mammary ducts. Accordingly, ectopically expressed G1P3 resulted in hyperplastic acini in MCF10A morphogenesis assays (Figure 2 ). The morphology of MCF10A G1P3 acini was distinct from multilobular neoplastic acini formed by ErbB-2 or c-Src oncogenes, but was similar to nonlobular preneoplastic acini formed by the overexpression of antiapoptotic or proliferative genes (Bcl2, Bcl-xL, Cyclin D1 or HPV E7) (Muthuswamy et al., 9 1 0 8 0 1 2 3 4 5 6 7 9 10 8 0 1 2 3 4 5 6 7 9 10 8 Figure 6 Kaplan-Meier analysis for the effect of elevated G1P3 expression on RFS and OS. (a, b) Kaplan-Meier analysis to define the effect of elevated G1P3 expression on RFS (a) and OS (b) in all breast cancer patients (n ¼ 674), ER negative (n ¼ 198) and ER positive (n ¼ 471). Elevated G1P3 expression was defined based on scaled RP approach as described in Materials and methods. P-values were calculated by Wald test as in multivariable analysis (Table 1) .
Role of the antiapoptotic factor G1P3 in breast cancer V Cheriyath et al 2001; Debnath et al., 2003; Nelson and Bissell, 2005) . This suggested that G1P3 overexpression may lead to preneoplastic lesions in breast epithelium. In vivo studies in mice may further validate and confirm the above postulate. Multiple modes of cell death including detachmentinduced cell death (anoikis) have been ascribed to the clearance of acinar luminal cells (Mailleux et al., 2008a, b) . Epithelial cells undergo anoikis as they lose contact with the extracellular matrix, which could partially check their outgrowth when receiving hyperproliferative signals from the tumor microenvironment (Reginato et al., 2003; Braig and Schmitt, 2006; Puisieux et al., 2006; Mailleux et al., 2007a) . Consistent with its antagonism of acinar luminal cell death, G1P3 inhibited anoikis (Figures 3a-c and Supplementary Figure 3) . The inhibitory effect of G1P3 on anoikis-induced mitochondrial potential loss suggests that G1P3 may augment breast cancer initiation by over-riding mitochondrialmediated apoptosis, allowing cells to acquire additional driver mutations.
Although mechanisms responsible for resistance to systemic therapies are multifactorial, evasion of apoptosis is a common characteristic of resistant tumors, including hormone-and therapeutic-resistant ER þ breast cancers (Jordan and O'Malley, 2007; GimenezBonafe et al., 2009; Eroles et al., 2010; Miller et al., 2010) . The antiapoptotic factor Bcl-2 is a direct target of estrogen signaling and has been implicated in drug resistance in vitro. However, in clinical studies, elevated expression of Bcl-2 and related antiapoptotic factors correlated with a good prognosis in breast cancer patients, perhaps because of its regulation by ER (Thomadaki et al., 2007; Callagy et al., 2008; Thomadaki and Scorilas, 2008; Dawson et al., 2010) . This paradoxical effect of Bcl-2 suggests the involvement of other hormonally controlled antiapoptotic factors like G1P3 in conferring therapeutic resistance in ER þ breast cancer. In agreement with this postulate, elevated expression of G1P3 conferred survival advantages to ER þ breast cancer cells (Figures 4 and 5 ) and resulted in tamoxifen resistance. This together with the breast cancer subtypeindependent overexpression of G1P3 (Figure 1 ) suggests that its antiapoptotic activity has a more pronounced effect on adverse outcomes in ER þ breast cancers. A better understanding of the critical factors that lead to recurrence or relapse of breast cancer will provide opportunities for targeted therapies. Our studies identified increased risk and shortened time of breast cancer relapse and OS in patients with elevated G1P3, which reinforces the potential role of G1P3 in cancer development and progression. HRs of elevated G1P3 were comparable to HRs of individual genes of Oncotype TM gene signature for elevated risk of breast cancer progression (Table 1; Ma et al., 2006) . Further, elevated expression of G1P3 in other cancer histologies, such as hepatocellular, head and neck and skin cancers, suggests that cancer-promoting activity of G1P3 may not be confined to breast cancer (Supplementary Table 3) . Hence, the antiapoptotic activity of G1P3 may be a more global promoter of neoplasms.
Materials and methods
Cell lines
MCF10A, MDA-MB-231, HCC68, HCC1569, MDA-MB-456, MDA-MB-436, BT-549 and HCC1937 were from ATCC (Manassas, VA, USA). MCF7 and MDA-MB-453 were a kind gift from Dr Pierre Triozzi (The Cleveland Clinic, Cleveland, OH, USA). HMECs were from Lonza (Cologne, Germany). All cell lines were propagated in the media recommended by the provider.
Reagents and antibodies
Reagents and their sources (within parentheses) are as follows: IFN-a2b (intron) (Scherring Corp. Kenilworth, NJ, USA; specific activity 2.6 Â 10 8 IU/mg of protein, IFN-b (Rebif; Serono Inc., Rockland, MA, USA), IFN-g (CIBA-GEIGY), 17b-estradiol, methylcellulose and poly-HEMA (SigmaAldrich, St Louis, MO, USA), growth factor reduced matrigel (BD Biosciences, San Jose, CA, USA), San Jose, CA 4 0 ,6-diamidino-2-phenylindole, Hoechst, propidium iodide, Yo-Pro stain and Prolong gold (Invitrogen Inc., Carlsbad, CA, USA). Antibodies and their sources (within parentheses) are as follows: anti-b-actin (Sigma-Aldrich), and monoclonal anti-ISG15 antibody (44), tubulin, PHB, Bcl-2, Bim, Bid and cleaved caspase 3 antibodies (Cell Signaling Inc., Danvers, MA, USA). Rabbit polyclonal antiserum against G1P3 (pAb609) was generated using a peptide antigen corresponding to the final 14 a.a. of G1P3 (YATHKYLDSEEDEE). The antiserum was purified by MAbTrap GII affinity chromatography kit (Amersham Bioscience, Uppsala, Sweden). 5 0 -Digitonin-labeled G1P3 and actin LNA probes were from Exiqon Inc. (Copenhagen, Denmark).
Plasmids and engineering of cell lines G1P3 cDNA from pQCXIP-HATG1P3 (Cheriyath et al., 2007) was PCR amplified with 5 0 -GTCGACGGATCCATGC GGCAGAAG-3 0 (G1P3-BamH1.F) as forward and 5 0 -TGAG GAGTAGGTCTCGCTAGAatTCT-3 0 (G1P3-EcoR1.R) as reverse primers. The amplicon was subcloned into BamH1 and EcoR1 sites of retroviral vector pQCXIP (Clontech Inc., Mountain View, CA, USA) to generate the G1P3 expression vector. MCF7 and MCF10A cells were transduced either with the vector (pQCXIP) or G1P3 pantropic virions as described (Cheriyath et al., 2007; Bae et al., 2008) . Stable pools of MCF7 cells were maintained in puromycin-containing selection media. Because of the observed negative effect of puromycin on transgene expression in MCF10A cells, after selection, MCF10A stable pools were maintained without puromycin.
Immunoblot analyses, TdT-mediated dUTP nick-end labeling assay and mitochondrial fractionation and membrane potential measurement Assays were performed as described (Cheriyath et al., 2007) .
Morphogenesis assay, indirect immunofluorescence and confocal microscopy Morphogenesis assay was carried out with passage-matched stable pools of MCF10A Vector or MCF10A G1P3 cells as described . Acini stained with 4 0 ,6-diamidino-2-phenylindole were imaged by confocal microscopy at Â 20 magnification with zoom set at 2. Images were collected at (0.65 nm) Z planes and three-dimensional images were reconstructed using the Velocity software (Mountain View, CA, USA). Activation of caspase 3 was determined by staining the acini on days 5, 8 and 10 with an antibody specific to cleaved caspase 3 as per the manufacturer's method (Cell Signaling Inc.) and confocal microscopy. For live staining, acini were incubated with Hoechst 33342 (5 mg/ml), Yo-Pro (100 nM) and propidium iodide (1 mg/ml) for 10 min in dark, followed by immunofluorescence microscopy with a Leica DMI4000B inverted microscope (Leica, Wetzlar, Germany).
